Head-to-head evidence
filgotinib vs upadacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanisms: JAK · JAK1 · full Rheumatoid Arthritis pipeline
filgotinib · Jyseleca
Marketed by Gilead Sciences and partners
NCT02873936 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 449 patients; the primary endpoint, ACR20 response at week 12 (a validated rheumatoid-arthritis disease-activity measure), was significantly higher with both filgotinib doses than placebo (66.0% and 57.5% vs 31.1%, both p<0.001).
Next expected readout: April 2029 · NCT06687551 (registry estimate)
upadacitinib · Rinvoq
Marketed by AbbVie
NCT02675426 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 661 patients using two validated rheumatoid arthritis disease-activity measures as co-primary endpoints, and both upadacitinib doses produced significantly higher response rates than placebo on both measures (all comparisons p<0.001).
Next expected readout: March 2027 · NCT07636057 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: filgotinib's landscape · upadacitinib's landscape